Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06443619
Other study ID # R.24.04.2582.
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 4, 2024
Est. completion date July 10, 2025

Study information

Verified date May 2024
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nearly 50% of patients suffer from chronic pain following breast cancer surgery. Several regional anesthesia techniques, including paravertebral block, erector spinae plane block, pectoral nerves block, and serratus anterior plane block, have been applied for acute pain control and prevention of chronic pain after breast cancer surgery. Exploiting the beneficial effect of glucose in regulating neuroinflammation and neuropathic pain, we hypothesize that the addition of glucose to bupivacaine could be superior to bupivacaine in ultrasound-guided SAPB in improving the quality of postoperative analgesia and preventing chronic pain after mastectomy. Patients will be randomly allocated into one of two equal groups (30 patients each ); the study group; Group I( B-D) (n=30): will receive unilateral USG-deep SAPB 0.4 ml/kg Of 0.25 % isobaric bupivacaine with addition of 15ml glucose 5% to (30 ml total volume); Group (B-N) (n=30): will receive unilateral USG-deep SAPB 0.4 ml/kg Of 0.25% isobaric bupivacaine to be diluted with 15ml isotonic saline (30 ml total volume). The occurence of postmastectomy pain, 3 months after surgery, will be the primary outcome.


Description:

Breast cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related death in women. Although early detection and treatment have increased survival rates, chronic postsurgical pain (CPSP) is one of the most common complications of breast cancer surgery. Nearly 50% of patients suffer from chronic pain following breast cancer surgery which is known as Post Mastectomy Pain Syndrome (PMPS). There are several risk factors for PMPS, including younger age, invasive surgical interventions, adjuvant radiation therapy following surgery, and high pain score in the early postoperative period. Several regional anesthesia (RA) techniques, including paravertebral block (PVB), pectoral nerves (PECS) block, and the erector spinae plane block (ESPB), have been applied for acute pain control and prevention of chronic pain after breast cancer surgery (BCS). Recently, the serratus anterior plane block (SAPB) has become a newer interfacial plane block that appears to be safe and easily performed under ultrasound (de la Torre et al., 2014). A study concluded that preoperative SAPB with ropivacaine reduced the prevalence of CPSP at 3 months postoperativelyfrom 51.7% to 25.6%. Various adjuvants like fentanyl, clonidine, magnesium sulphate, nalbuphine, and dexamethasone have been used with bupivacaine in different blocks for prolonging the duration of analgesia and prevention of chronic pain. Using glucose 5% has been progressively applied to treat many peripheral entrapment neuropathies and has been proven to have outstanding effects in a few high-quality studies. Glucose 5% could decrease neurogenic inflammation by impeding the discharge of substance P and calcitonin gene-related peptides, which are pro-nociceptive substances that contribute to neurogenic inflammation and neuropathic pain. Exploiting the beneficial effect of glucose in regulating neuroinflammation and neuropathic pain, we hypothesize that the addition of glucose, as an adjuvant, to bupivacaine in the regional anesthesia technique for breast surgery could improve the quality of postoperative analgesia and prevent chronic pain after mastectomy. We hypothesize that the addition of glucose to bupivacaine could be superior to bupivacaine in ultrasound-guided SAPB in improving the quality of postoperative analgesia and preventing chronic pain after mastectomy. This randomized, double-blind study was designed to compare the efficacy and safety of co-administration of glucose and bupivacaine (study group), and bupivacaine alone (control group) in ultrasound-guided SAPB in patients undergoing modified radical mastectomy using the occurence of postmastectomy pain, 3 months after surgery, as the primary outcome.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 190
Est. completion date July 10, 2025
Est. primary completion date June 4, 2025
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologists physical status I-II - age ranging from 20 to 60 years - scheduled for unilateral modified radical mastectomy Exclusion Criteria: - patient refusal to participate in the study - infection at site of needle insertion - hypersensitivity to the studied drugs - psychotic disorders, - bilateral MRM , - bleeding disorder - chronic renal or hepatic diseases

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
unilateral USG-deep SAPB with glucose
patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
unilateral USG-deep SAPB without glucose
will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of chronic pain (post mastectomy pain syndrome) The prevalence of chronic pain (post mastectomy pain syndrome) of any severity: Numerical pain scale (NRS) >0 on a 0 - 10 scale 3 months after surgery
Secondary Numerical pain scale (NRS) Numerical pain scale (NRS) on a 0 - 10 scale, o no pain, 10 worst pain over 24 hours
Secondary Postoperative opioid consumption. total consumption of morphine in the first 24 hours over 24 hours
Secondary Patient satisfaction with pain management Patient satisfaction with pain management assessed 24 h after surgery using an 11-point Likert scale (range, 0-10: 0, entirely unsatisfied; 10,fully satisfied). 24 hours
Secondary The severity of CPSP and its impact on daily function The severity of CPSP and its impact on daily function assessed 3 and 6 months after surgery using the revised brief pain inventory (BPI) Chinese-Simplified version 3 and 6 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04874038 - Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) Phase 3
Recruiting NCT06087211 - Pain Relieving Potentials of Combination of Oral Duloxetine and Intravenous Magnesium Sulphate in Post Mastectomy Pain Phase 4
Completed NCT02240199 - Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain Phase 3
Recruiting NCT05201963 - Erector Spinae Plane Block Versus Serratus Anterior Block on Post Mastectomy Pain Syndrome N/A
Completed NCT05458154 - Evaluation and Re-evaluation of Post-mastectomy Pain Syndrome by Breast Cancer EDGE Task Force Outcomes N/A
Recruiting NCT05935059 - The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery. N/A
Not yet recruiting NCT04317898 - Ultrasound-Guided Serratus Plane Block Vs Paravertebral Block For Chronic Post-mastectomy Pain. N/A
Active, not recruiting NCT04267315 - Trigger Point Injections for Post-Mastectomy Pain Syndrome Phase 2
Recruiting NCT05771103 - Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post Mastectomy Pain N/A
Recruiting NCT03965442 - Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome
Not yet recruiting NCT04989179 - Incidence and Factors Affecting the Development and Outcome of Post Mastectomy Pain Syndrome
Recruiting NCT05770596 - Vitamin C on Acute and Chronic Post Mastectomy Pain N/A